Abstract

Background: Laryngoscopy and tracheal intubation provokes a transient and marked sympathetic response that manifests as an increase in heart rate& blood pressure, with the potential for development of cardiovascular events. Since Dexmedetomidine has good bioavailability and rapid absorption through nasal mucosa, we conducted this study to evaluate the effects of nebulised dexmedetomidine Aim: To evaluate the effect of nebulized dexmedetomidine in attenuating the haemodynamic response to laryngoscopy and tracheal intubation. Methods: This prospective, randomised, comparative study was conducted in 80 American Society of Anaesthesiologists (ASA) I&II patients. The primary outcome was to evaluate the effects of dexmedetomidine nebulisation in blunting the stress response to laryngoscopy and intubation. The study population was divided randomly into two groups. Control group C (n = 40) received nebulisation with 5 ml of normal saline and group D (n = 40) received 1 µg/kg dexmedetomidine 5 ml10 min before induction in sitting position. Results: Demographics were comparable. Following laryngoscopy and intubation, systolic (SBP), diastolic (DBP) and mean arterial pressure (MAP) were markedly increased in the control group whereas in group D there was a fall in SBP, DBP, MAP & Heart rate at 1min,5 min &10 min following intubation, which was statistically significant (P< 0.001). Conclusion: Nebulised dexmedetomidine effectively blunts the stress response to laryngoscopy and intubation with no adverse effects.

Description